Chardan Capital Analyst Downgrades uniQure Price Target to $35.00, Maintains Buy Rating

Chardan Capital analyst Daniil Gataulin maintained a "Buy" rating on uniQure (QURE) with a revised price target of $35.00, down 7.89% from the previous target of $38.00. The average one-year price target for uniQure is $36.27, implying an upside of 165.15% from the current price. The average brokerage recommendation is 1.8, indicating "Outperform" status.

Chardan Capital Markets LLC has maintained its "Buy" rating on uniQure NV (NASDAQ: QURE), but has revised its price target to $35.00 per share, a decrease of 7.89% from the previous target of $38.00. This decision is based on the company's robust pipeline of innovative gene therapies and recent clinical advancements, according to the firm's analyst, Daniil Gataulin.

uniQure, a biotechnology company focused on gene therapies, has been making strides in its pipeline. The company's lead product, Glybera, has shown promising results in clinical trials, and its other gene therapies are in various stages of development. Chardan's analyst highlights uniQure's strong intellectual property portfolio and strategic partnerships as key drivers for growth.

In a recent update, uniQure announced a significant milestone in its clinical trials for a new gene therapy, further bolstering the company's prospects. The analyst at Chardan Capital notes that this progress aligns with the company's long-term vision and could lead to significant market opportunities.

Despite the recent downward adjustment in the price target, the average one-year price target for uniQure remains at $36.27, implying an upside of 165.15% from the current price. The average brokerage recommendation is 1.8, indicating an "Outperform" status.

The biotechnology sector is known for its high volatility and intense competition. While uniQure's recent stock performance has been mixed, with analysts' ratings ranging from "buy" to "sell," the company's strong fundamentals and promising pipeline continue to attract investor interest.

The latest financial report from uniQure showed a loss of $0.69 per share, outperforming analyst expectations. However, the company continues to show a negative net margin and return on equity, indicating that it is still in the early stages of growth and development.

Institutional investors have also shown confidence in uniQure, with large investors such as Vestal Point Capital LP, Nantahala Capital Management LLC, and Aberdeen Group plc increasing their positions in the company's stock. As of the latest data, 78.83% of uniQure's stock is owned by hedge funds and other institutional investors.

Chardan Capital's revised price target reflects the firm's belief in uniQure's potential to generate substantial value for shareholders. The analyst acknowledges that the biotechnology sector is highly competitive and volatile, but remains optimistic about uniQure's ability to execute its strategy and deliver on its promises.

References:
[1] https://www.ainvest.com/news/chardan-capital-maintains-buy-rating-uniqure-35-pt-2507/
[2] https://www.marketbeat.com/instant-alerts/uniqure-nasdaqqure-stock-price-down-64-time-to-sell-2025-07-29/